Pharmaxis Signs Second Agreement with Chiesi
Release Date: 08/05/2015 12:00am
Pharmaceutical company Pharmaxis (ASX: PXS) today announced it has entered into an exclusive distribution and supply agreement with global pharmaceutical company Chiesi Farmaceutici SpA (Chiesi) for the commercialisation of Bronchitol® (mannitol) for cystic fibrosis in adults aged 18 years and above in Germany, the United Kingdom and Ireland.
Under the terms of the agreement Chiesi will take over responsibility for the marketing, sales and distribution of Bronchitol from June 2015. The product was launched in Germany in 2012, in the United Kingdom in 2013 and is planned to be launched in Ireland after the current assessment for reimbursement is concluded. Germany and the United Kingdom account for more than ninety five percent of current European sales.
Categories: News and Media